New drug cocktail targets brain tumors from lung and breast cancer
NCT ID NCT07449481
First seen Mar 08, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This Phase 2 trial tests a combination of two drugs, utidelone and bevacizumab, with or without a third drug called etoposide, in 56 patients with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and improve outcomes. Participants will receive the drugs intravenously in 21-day cycles, continuing as long as they benefit or until side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
utidelone and bevacizumab, with or without etoposide
What this could lead to
If successful, this could offer a new drug combination to shrink brain metastases from lung or breast cancer, potentially improving survival and quality of life.
What could go wrong
This is an early Phase 2 trial with only 56 participants, so results may not apply broadly. Side effects like nerve damage from utidelone are possible, and the combination may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.